Study S000466

BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03341429
Acronym: BARIOPTIMISE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 70
Start: 2018-08-22
Primary completion: 2019-11-28
Lead sponsor: University College, London
Conditions: Obesity
Interventions: DRUG:Liraglutide Pen Injector [Saxenda]; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

%WL [24 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017334	Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial. Mok J, JAMA surgery	2023	Randomized trial	PMID 37494014 DOI	cites ClinicalTrials.gov:NCT03341429; registry reference DERIVED:37494014
R0026203	Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Blackman A, International journal of obesity (2005)	2016	Randomized trial	PMID 27005405 DOI	registry reference BACKGROUND:27005405
R0027008	Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Pajecki D, Revista do Colegio Brasileiro de Cirurgioes	2013	Nonrandomized study	PMID 23912365 DOI	registry reference BACKGROUND:23912365